import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: 'tirzepatide-complete-guide-2026',
  title: 'Tirzepatide: The Complete Research Guide (2026)',
  description:
    'A comprehensive 2026 research guide to tirzepatide — the first dual GLP-1/GIP receptor agonist. Covers mechanism of action, preclinical and clinical data, dosing protocols, metabolic endpoints, and sourcing standards for research use.',
  category: 'Compound Profiles',
  readMinutes: 14,
  publishedAt: '2026-06-08',
  ogImage: '/og-image.jpg',
  body: [
    {
      type: 'paragraph',
      text: 'Tirzepatide is a synthetic 39-amino-acid peptide that co-activates two incretin receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This dual agonism distinguishes it from earlier GLP-1-only agents and has produced metabolic outcomes that have redefined the research landscape for obesity, type 2 diabetes, and related cardiometabolic conditions.',
    },
    {
      type: 'heading',
      text: 'What Is Tirzepatide?',
    },
    {
      type: 'paragraph',
      text: 'Developed by Eli Lilly and approved under the brand names Mounjaro (T2D) and Zepbound (obesity) by the FDA in 2022 and 2023 respectively, tirzepatide is a once-weekly subcutaneous injection. For research purposes, it serves as a reference compound to study dual incretin biology, appetite regulation, lean mass preservation, and cardiometabolic endpoints.',
    },
    {
      type: 'list',
      items: [
        'Molecular weight: ~4,813 Da (with fatty diacid C20 linker)',
        'Sequence: Modified GIP(1-39) backbone with GLP-1R agonist activity',
        'Half-life: approximately 5 days (weekly dosing in clinical use)',
        'Administration route: subcutaneous injection (research and clinical)',
        'Receptor targets: GLP-1R (lower potency than semaglutide) + GIPR (high potency)',
      ],
    },
    {
      type: 'heading',
      text: 'Mechanism of Action: Dual Incretin Agonism',
    },
    {
      type: 'subheading',
      text: 'GLP-1 Receptor Activation',
    },
    {
      type: 'paragraph',
      text: 'Tirzepatide\'s GLP-1R activity drives the familiar incretin effects: glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and central appetite suppression via hypothalamic circuits. Unlike semaglutide, tirzepatide acts as a partial agonist at GLP-1R — but the combined dual receptor engagement produces superior metabolic outcomes in comparative studies.',
    },
    {
      type: 'subheading',
      text: 'GIP Receptor Activation',
    },
    {
      type: 'paragraph',
      text: 'The GIP axis was historically considered redundant or even counterproductive in obesity models. Tirzepatide\'s clinical success challenged that assumption. At GIPR, tirzepatide appears to act as a full agonist, with research suggesting GIPR signaling contributes to adipose tissue remodeling, energy expenditure, and lean mass preservation — effects not fully explained by GLP-1R biology alone.',
    },
    {
      type: 'subheading',
      text: 'Central vs. Peripheral Effects',
    },
    {
      type: 'paragraph',
      text: 'Both GLP-1R and GIPR are expressed in the hypothalamus, brainstem, and other CNS regions. Research in rodent models demonstrates that dual receptor agonism produces greater suppression of food intake than either single agonist alone, suggesting synergistic central effects on appetite circuitry — potentially mediated through arcuate nucleus and paraventricular nucleus pathways.',
    },
    {
      type: 'heading',
      text: 'Key Research Findings (SURMOUNT & SURPASS Trials)',
    },
    {
      type: 'paragraph',
      text: 'The SURMOUNT and SURPASS clinical trial programs generated the most comprehensive dataset on any obesity/metabolic peptide to date:',
    },
    {
      type: 'list',
      items: [
        'SURMOUNT-1 (2022): 15 mg dose achieved mean 22.5% body weight reduction over 72 weeks vs. 2.4% placebo — the largest weight loss of any approved pharmacotherapy in history',
        'SURPASS-2 (2021): Tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide 1 mg in T2D patients',
        'SURMOUNT-4 (2024): Discontinuation trial — weight regain of ~14% by week 88 after stopping, confirming metabolic dependency similar to other incretin therapies',
        'SURPASS-CVOT (2025): Demonstrated significant reduction in 3-point MACE in T2D patients with established cardiovascular disease',
        'Body composition sub-studies: ~17-18% fat mass reduction with partial lean mass preservation, improved with resistance exercise co-intervention',
      ],
    },
    {
      type: 'heading',
      text: 'Preclinical Research Endpoints',
    },
    {
      type: 'paragraph',
      text: 'Tirzepatide has been studied in rodent and primate models across several mechanistic domains relevant to researchers:',
    },
    {
      type: 'subheading',
      text: 'Adipose Tissue Biology',
    },
    {
      type: 'paragraph',
      text: 'Mouse models treated with tirzepatide show enhanced browning of white adipose tissue (WAT), increased UCP-1 expression, and elevated energy expenditure beyond caloric restriction alone. GIPR activation is hypothesized to drive this effect, as it is not replicated with GLP-1-only agonists at equivalent weight-loss doses.',
    },
    {
      type: 'subheading',
      text: 'Hepatic Steatosis',
    },
    {
      type: 'paragraph',
      text: 'In diet-induced obese (DIO) mouse models, tirzepatide reduces liver triglyceride content, ALT/AST enzyme levels, and histological NAFLD/NASH scores. Clinical data from SURMOUNT-NASH (2024) confirmed ≥50% improvement in NASH histology in ~62% of tirzepatide-treated subjects vs. 10% placebo.',
    },
    {
      type: 'subheading',
      text: 'Lean Mass Preservation',
    },
    {
      type: 'paragraph',
      text: 'A critical research question for all GLP-1-class peptides is lean mass preservation during weight loss. SURMOUNT-1 body composition analyses showed ~16-17% of total weight loss was lean mass — comparable to bariatric surgery ratios. Ongoing research examines whether resistance training, leucine supplementation, or GH-axis peptide co-administration can further preserve muscle during tirzepatide-induced caloric deficit.',
    },
    {
      type: 'heading',
      text: 'Research Protocol Design',
    },
    {
      type: 'subheading',
      text: 'Rodent Dosing Reference',
    },
    {
      type: 'paragraph',
      text: 'In preclinical mouse models, tirzepatide is typically administered subcutaneously at doses ranging from 0.03 to 3 nmol/kg body weight (roughly equivalent to 0.01–1 mg/kg). DIO mouse studies commonly use 3–10 nmol/kg as a "high dose" comparator. Rats require dose adjustment due to differences in receptor expression density.',
    },
    {
      type: 'list',
      items: [
        'Low dose murine: 0.03–0.1 nmol/kg/day (mechanistic threshold studies)',
        'Mid dose murine: 0.3–1 nmol/kg/day (standard metabolic studies)',
        'High dose murine: 3–10 nmol/kg/day (maximal efficacy/comparison studies)',
        'Frequency: Daily or every-other-day in mouse models (vs. weekly human)',
        'Route: Subcutaneous injection preferred; intraperitoneal used in some acute studies',
      ],
    },
    {
      type: 'subheading',
      text: 'Key Endpoints to Track',
    },
    {
      type: 'list',
      items: [
        'Body weight and food intake (daily measurements)',
        'Fasting glucose and HbA1c (weekly)',
        'Insulin tolerance test (ITT) and glucose tolerance test (GTT)',
        'Body composition (EchoMRI or DEXA at baseline, mid-point, endpoint)',
        'Liver histology, ALT/AST, hepatic triglycerides',
        'Energy expenditure (metabolic cage, O2 consumption)',
        'Adipose tissue browning markers (UCP-1, PGC-1α)',
        'Lean mass biomarkers (grip strength, muscle cross-section)',
      ],
    },
    {
      type: 'heading',
      text: 'Comparing Tirzepatide to Other GLP-1 Class Compounds',
    },
    {
      type: 'table',
      headers: ['Compound', 'Receptors', 'Mean Weight Loss', 'HbA1c Reduction', 'Half-life'],
      rows: [
        ['Tirzepatide 15 mg', 'GLP-1R + GIPR', '~22.5%', '~2.46%', '~5 days'],
        ['Semaglutide 2.4 mg', 'GLP-1R', '~15.2%', '~1.86%', '~7 days'],
        ['Retatrutide 12 mg', 'GLP-1R + GIPR + GcgR', '~24.2%', '~2.02%', '~6 days'],
        ['Liraglutide 3.0 mg', 'GLP-1R', '~8.4%', '~1.4%', '~13 hours'],
      ],
    },
    {
      type: 'heading',
      text: 'Storage and Handling',
    },
    {
      type: 'paragraph',
      text: 'Tirzepatide for research use should be stored lyophilized at -20°C and reconstituted in sterile bacteriostatic water (0.9% benzyl alcohol) or sterile saline before use. Reconstituted solutions should be stored at 4°C and used within 28 days. Protect from UV exposure and avoid freeze-thaw cycles after reconstitution.',
    },
    {
      type: 'list',
      items: [
        'Lyophilized storage: -20°C (up to 2 years from manufacture)',
        'Reconstitution solvent: bacteriostatic water or sterile saline',
        'Post-reconstitution: 4°C, use within 28 days, protect from light',
        'Do not shake vigorously — swirl gently to dissolve',
        'Verify purity ≥98% HPLC and confirm mass spec identity before use',
      ],
    },
    {
      type: 'heading',
      text: 'Sourcing Standards for Research',
    },
    {
      type: 'paragraph',
      text: 'Given the complexity of tirzepatide\'s structure — a 39-amino-acid peptide with a C20 fatty diacid linker — synthesis quality varies significantly between vendors. Researchers should require HPLC purity documentation (≥98%), ESI-MS or MALDI-TOF mass confirmation, and LAL endotoxin testing on each lot. Single-use certificates of analysis from in-house testing are insufficient; third-party accredited lab documentation is the standard for serious research programs.',
    },
    {
      type: 'callout',
      text: 'Nexphoria provides lot-specific HPLC and mass spectrometry documentation for all peptides including complex dual-agonist and GLP-1 class compounds. Third-party accredited testing is standard on every batch.',
    },
    {
      type: 'disclaimer',
      text: 'Tirzepatide is sold by Nexphoria strictly for laboratory research purposes. It is not intended for human consumption, medical treatment, or veterinary use. All information presented here is for educational and research design purposes only.',
    },
  ],
};
